朱俊生：第三支柱是養老基金積累最重要的力量 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Share:
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx s existing bone franchise
Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of world
Mereo receives $50 million upfront and is eligible for milestones up to $254 million
NOVATO, Calif., LONDON, and REDWOOD CITY, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (NASDAQ:MREO, AIM: MPH)), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human mono
Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYXTM (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels ( 50 ng/dL) through 48 weeks in the Phase 3 HERO study
Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved ORGOVYX™ (relugolix) for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Re
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Yamana Gold Announces the Completion of the Integration of the Agua Rica Project and the .
Yamana GoldDecember 18, 2020 GMT
TORONTO, Dec. 18, 2020 (GLOBE NEWSWIRE) YAMANA GOLD INC. (TSX: YRI; NYSE: AUY; LSE: AUY) (“Yamana”) is pleased to announce the completion of the integration of the Agua Rica project with the Minera Alumbrera plant and infrastructure. Going forward, the integrated project will be known as the MARA Project.
The integration creates significant synergies by combining existing substantive infrastructure which was formerly used to process ore from the Alumbrera mine during its mine life, including processing facilities, a fully permitted tailings storage facility, pipeline, logistical installations, ancillary buildings, and other infrastructure, with the future open pit Agua Rica mine. Relatively modest modifications to the existing processing circuit will be impl